About SphingoTec
SphingoTec develops and markets innovative solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice. We develop biomarkers addressing diagnostically underserved critical care conditions such as acute kidney injury, sepsis, and acute heart failure. First and foremost, our biomarkers support better management of critically ill patients, where fast and reliable information is of the essence in taking treatment decisions.
Our mission
To improve patient outcomes with innovative diagnostic solutions for acute and critical care.
Actionable insights in real-time.
Our products
SphingoTec is a privately held company with a long history of biomarker discovery, development, and validation. Our innovative biomarkers are available as microtiter plate assays. The microtiter plate is a standard tool in analytical research and laboratories. It is a high-throughput solution, allowing the measurement of 41 patient samples at once. SphingoTec’s microtiter plate assays are based on a chemiluminescence sandwich immunoassay technology.
Kidney function biomarker penKid
The limitations of the current standard of care diagnostics for acute kidney injury are well known, thus is the need to implement new biomarkers to assist better management of acute kidney injury. Timely information on kidney function is crucial to early initiate and adapt renal replacement therapy and nephro-protective strategies.
Endothelial function biomarker bio-ADM
Endothelial dysfunction is a hallmark of many acute and critical care conditions, such as sepsis and acute heart failure. Loss of endothelial function causes the formation of edema, shock, and subsequent organ failure.
Management Team
Advisory board
